Xstrahl to Showcase Dual Modality Treatment Solution for Dermatologists at NorCal 2024

May 1, 2024

Xstrahl to Showcase Dual Modality Treatment Solution at NorCal 2024 in Napa, CA
Radiant™ Aura is a painless, non-surgical office-based radiation therapy treatment option for patients with non-melanoma skin cancers and keloid scarring



Radiant Aura is the only dual modality surface radiation therapy system that enables you to choose either electronic brachytherapy or SRT based on the needs of your patients.

Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the CalDerm 2024 NorCal Conference at the Meritage Resort & Spa from May 3-5 in Napa, CA.

“We’re pleased showcase Radiant Aura at this year’s NorCal meeting. Radiant Aura is a painless non-surgical skin cancer treatment alternative available to support the delivery of office-based radiation therapy for patients with NMSC when surgery is not possible, contraindicated, or simply not preferred due to cosmetic concerns,” said Adrian Treverton, CEO of Xstrahl.

Radiant Aura is a low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring. It is the only dual modality system that offers both non-invasive electronic brachytherapy (eBt) and superficial radiation therapy (SRT) for NMSC and keloid scarring. The device received U.S. Food and Drug Administration (FDA) 510(k) clearance in July 2023. It is commercially available now and available for sale across the US.

Visit Xstrahl at CalDerm 2024 NorCal at the Meritage Resort & Spa from May 3-5, 2024.

*To be placed on the VIP List for private events at the conference, please email kristinaminkovitz@xstrahl.com

# # #

For further information, please contact:
Kelly Withers, National Sales Director
Cell: 602-509-4990 or e-mail: kellywithers@xstrahl.com

About Xstrahl
Xstrahl is a medical technology company that designs radiation delivery devices to support clinical teams and cancer researchers. For more than 25 years, Xstrahl has been shaping the development of superficial and orthovoltage radiation therapy and advancing preclinical radiation research. Xstrahl systems are in operation at more than 700 treatment and research facilities worldwide.

To learn more about Radiant Aura, visit www.xstrahl.com/norcalderm-2024/
To learn more about all Xstrahl clinical and research systems, visit www.xstrahl.com



Contact Us

Find out more about how Xstrahl will work tirelessly for you

Explore Related Posts